Identifiers
Calneurin sense has no documented commercial or clinical applications in the available evidence. The ingredient name is non-standard, and no formulation, consumption, production, or therapeutic use data were found. Regulatory records indicate it is a chemical substance listed on the U.S. TSCA Inventory and subject to an active TSCA 5(a) Final SNUR, but these listings do not specify any application role. Researchers should treat calneurin sense as an uncharacterized substance with no established functional use until further data are available.
No product or formulation problem is documented for calneurin sense. The available evidence contains no descriptions of functional benefits, performance improvements, or formulation challenges that this ingredient addresses. Its TSCA Inventory listing and active SNUR status indicate regulatory oversight but do not imply any problem-solving role. Without formulation or use data, any claim that calneurin sense solves a specific product issue would be unsupported. Formulators should not assume a functional benefit until evidence emerges.
There is no evidence supporting any commercial or clinical use of calneurin sense. The ingredient is not listed in therapeutic use records, WHO essential medicines, or any formulation or consumption pattern data. Its presence on the TSCA Inventory and the active TSCA 5(a) Final SNUR are regulatory statuses, not evidence of market adoption or efficacy. Researchers should conclude that calneurin sense lacks substantiated uses, and any product development involving it would require new safety and efficacy data.
Formulation trade-offs for calneurin sense cannot be assessed because no physicochemical, stability, compatibility, or concentration data are available. The only relevant constraint is regulatory: it is listed on the TSCA Inventory and subject to an active TSCA 5(a) Final SNUR in the U.S., and it appears under REACH Annex XVII restrictions in the EU. These restrictions may limit or condition its use, but the specific entry details are not fully specified. Researchers must obtain substance-specific data before evaluating any formulation trade-offs.
| Property | Value | Category |
|---|---|---|
| solubility | H2O: soluble | Formulation Relevant Properties |
| Density | 1.4388 (rough estimate) | Handling Relevant Properties |
| specific activity | ≥2,500 units/mg protein, ≥2,500units/mg protein | Analytical Properties |
| mol wt | dimer ~77 kDa, subunit mol wt 19-58 kDa | Analytical Properties |
| composition | Protein, 0.3-1.7% Lowry | Analytical Properties |
| storage temp | −20°C, Keep in dark place,Sealed in dry,Room Temperature | Analytical Properties |
| CAS No. | 90371-51-0 | Analytical Properties |
| Melting point | 200 °C | Analytical Properties |
| Boiling point | 662.7°C (rough estimate) | Analytical Properties |
| bulk density | 600kg/m3 | Analytical Properties |
No formulation benchmark can be established for calneurin sense because it has no documented use, function, or comparable product data. Unlike ingredients with known application profiles, calneurin sense lacks any formulation, concentration, or co-ingredient information that would allow benchmarking. The only contextual data are regulatory listings, which do not provide a functional reference point. Researchers should treat calneurin sense as an unbenchmarked substance and avoid extrapolating from unrelated ingredients.